Sagitta Biotech is developing innovative therapies against infectious diseases and cancer based on its viral vector/mRNA platform.
The technology allows us to develop very quickly vaccines that are safe and effective, but also to manufacture them at a very low cost (cents per dose) thanks to a "constant manufacturing process" (identical for all vaccines).
This allows us to get significant shortcuts during development, and reduce the cost of operations for our customers.